Cascade Biotechnology is a biotechnology company developing complementary therapeutics drugs to treat and manage central nervous system and peripheral nervous system diseases and disorders that is headquartered in South Brunswick Township, New Jersey and was founded in 2018 by David C. Fritzinger, Daniel E. Benjamin and Edwin Holland.
Drug candidates in development by Cascade Biotechnology are made to complement the body's natural disease fighting systems to treat diseases and disorders such as Alzheimer’s disease (AD), schizophrenia (SZ), myasthenia gravis (MG), Neuromyelitis Optica (NMO), cancer, adult macular degeneration (ADM), blood diseases such as paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) and others.
On September 21, 2018 Cascade Biotechnology received an undisclosed amount of NIH Funding (Grant Number: 1 R43 HL139170-01A1) for a project titled "Preparation and development of a stabilized C3 analog for the treatment of paroxysmal nocturnal hemoglobinemia."
Daniel E. Benjamin, Ph.D.
David C. Fritzinger, Ph.D.
Duncan P Taylor